ReviewGlobal cardiology science & practice2018
Alcohol septal ablation in hypertrophic cardiomyopathy.
Review in Global cardiology science & practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Multimodality Imaging in Hypertrophic Cardiomyopathy: From Phenotyping to Precision Clinical Management.Diagnostics (Basel, Switzerland) · 2026Review
- Long-Term Impact of Frailty on Outcomes Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy.JACC. Advances · 2026Article
- Mitral Valve Abnormalities as Predictors of Procedural Success in Alcohol Septal Ablation: A Pilot Study.Journal of clinical medicine · 2026Article
- Socioeconomic Disparities in Patients Undergoing Alcohol Septal Ablation for Hypertrophic Cardiomyopathy.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: do mitral valve leaflet length, septal thickness, or sex affect the outcome?Cardiovascular intervention and therapeutics · 2024Article
- Extended septal myectomy versus alcohol septal ablation: clinical results at a national referral centre.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers.Medicina (Kaunas, Lithuania) · 2023Review
- A Narrative Review of Emerging Therapies for Hypertrophic Obstructive Cardiomyopathy.Current cardiology reviews · 2023Review
- Targeting the sarcomere in inherited cardiomyopathies.Nature reviews. Cardiology · 2022Review
- Left Septal Fascicular Block Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy.Journal of atrial fibrillationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved. In this review, we discuss indications, technical aspects, clinical results and patient selection to ASA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.